SCHEMBL14073369

SCHEMBL14073369

COc1ccccc1NC(=O)N1CCCN(c2nc3cc(C)cc(C)c3cc2C#N)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFTR P13569 7/20 0.70
▸ KDM4E B2RXH2 6/20 0.58
▸ KMT2A Q03164 5/20 0.58
▸ ALDH1A1 P00352 5/20 0.58
▸ TSHR P16473 4/20 0.58
▸ CASP1 P29466 4/20 0.58
▸ CASP7 P55210 4/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ LMNA P02545 3/20 0.58
▸ MAPK1 P28482 2/20 0.58
▸ ATM Q13315 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ P2RY12 Q9H244 2/20 0.57
▸ HSD17B10 Q99714 4/20 0.56
▸ ALOX15 P16050 2/20 0.56
▸ MAPT P10636 2/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ HPGD P15428 2/20 0.53
▸ USP2 O75604 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2524666 0.90 CFTR (0.65) CFTRKDM4EKMT2AALDH1A1TSHR
SCHEMBL12213255 0.87 CFTR (0.69) CFTRKDM4EKMT2AALDH1A1TSHR
SCHEMBL14235358 0.82 CFTR (1.00) CFTRKDM4EKMT2AALDH1A1TSHR
SCHEMBL5016780 0.79 KDM4E (0.71) CFTRKDM4EKMT2AALDH1A1TSHR
SCHEMBL14073364 0.77 ALDH1A1 (0.70) CFTRKDM4EKMT2AALDH1A1TSHR
SCHEMBL5016782 0.76 KDM4E (0.73) CFTRKDM4EKMT2AALDH1A1TSHR
SCHEMBL14235359 0.75 CFTR (1.00) CFTRKDM4EKMT2AALDH1A1TSHR
SCHEMBL12043094 0.75 KDM4E (0.85) CFTRKDM4EKMT2AALDH1A1TSHR
SCHEMBL12043100 0.75 MEN1 (0.69) CFTRKDM4EKMT2AALDH1A1TSHR
SCHEMBL14235249 0.75 CFTR (1.00) CFTRKDM4EKMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234253-A1 Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration NEURONASCENT, INC. (US) 2008-09-25 — — US disclosed
US-20080234253-A1 Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration NEURONASCENT, INC. (US) 2008-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234253-A1 Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration DCX, BDNF, GAP43 CFTR 3437/4885KDM4E 4443/4885KMT2A 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback